ARXX Therapeutics ApS: Financial statements 2021
CVR: 40868151
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
ARXX Therapeutics ApS (CVR 40868151) has filed annual accounts for 2021. In 2021, the company reported revenue of DKK 2,396,646 and a net result of DKK 77,355. The profit margin was 3.2%. Equity in the 2021 report amounted to DKK 177,355. The solvency ratio was 24.3%.
- Revenue
- DKK 2,396,646
- Gross Profit
- DKK 1,654,354
- Profit/Loss
- DKK 77,355
- Equity
- DKK 177,355
- Total Assets
- DKK 728,839
Official annual report
Find more companies like ARXX Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
ARXX Therapeutics ApS has published its interim report for the period October 1, 2019 to December 31, 2020.
About ARXX Therapeutics ApS
ARXX Therapeutics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Berte Aagot Hedding Poulsson and Jonas Hallén. The company is owned by ARXX THERAPEUTICS AS. The company has 2 employees (2026). In 2025, the company reported revenue of DKK 3,743,522 and a net result of DKK 706,595 compared with DKK 116,729 the year before. Equity in the 2025 report amounted to DKK 1,688,804.